Jackie Zima-Evans

The FDA approved elinzanetant (Lynkuet), a new type of nonhormonal drug to treat disruptive menopausal hot flashes. medpagetoday.com/obgyn/menopaus…

Germany's Bayer said on Friday the U.S. health regulator has approved its drug for menopause relief. The drug, branded as Lynkuet, is a non-hormonal treatment designed to relieve moderate-to-severe vasomotor symptoms, also known as hot flashes, associated with menopause. yahoo.com/news/articles/…

The FDA has approved Lynkuet, a new daily pill from Bayer that provides a non-hormonal option for treating hot flashes, common during menopause. Treating its symptoms has long been difficult because the transition affects multiple systems — temperature regulation, sleep, mood, bones, and sexuality — and the hormonal shifts vary widely among individuals. Hormone therapy is considered the most effective treatment for hot flashes and night sweats, but it is not suitable for everyone, especially women with a history of breast cancer. Lynkuet, known generically as elinzanetant, is the second medication to directly target the brain pathways involved in body temperature control. Click here to learn more about how the daily pill works. cbsn.ws/3WYIa3f

#NEWS: The @EU_Commission has approved our combination therapy for adult patients with newly diagnosed #MultipleMyeloma eligible for transplant. Learn more ⬇️ spkl.io/6014AH8cj

📖𝘖𝘶𝘳 𝘭𝘢𝘵𝘦𝘴𝘵 @TheIACH 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘊𝘭𝘶𝘣: 𝗜𝘀𝗮𝘁𝘂𝘅𝗶𝗺𝗮𝗯 𝗦𝘂𝗯𝗰𝘂𝘁𝗮𝗻𝗲𝗼𝘂𝘀 𝗯𝘆 𝗢𝗻-𝗕𝗼𝗱𝘆 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗦𝘆𝘀𝘁𝗲𝗺 𝘃𝘀 𝗜𝘀𝗮𝘁𝘂𝘅𝗶𝗺𝗮𝗯 𝗜𝗻𝘁𝗿𝗮𝘃𝗲𝗻𝗼𝘂𝘀 𝗣𝗹𝘂𝘀 𝗣𝗼𝗺𝗮𝗹𝗶𝗱𝗼𝗺𝗶𝗱𝗲 𝗮𝗻𝗱 𝗗𝗲𝘅𝗮𝗺𝗲𝘁𝗵𝗮𝘀𝗼𝗻𝗲 𝗶𝗻 𝗥𝗲𝗹𝗮𝗽𝘀𝗲𝗱/𝗥𝗲𝗳𝗿𝗮𝗰𝘁𝗼𝗿𝘆 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗠𝘆𝗲𝗹𝗼𝗺𝗮: 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗜𝗥𝗔𝗞𝗟𝗜𝗔 𝗦𝘁𝘂𝗱𝘆 📽️𝘕𝘰𝘸 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘰𝘯 𝘥𝘦𝘮𝘢𝘯𝘥! 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗳𝗼𝗿 𝗙𝗥𝗘𝗘 🔗iach.org/courses/multip… 𝘛𝘩𝘪𝘴 𝘸𝘦𝘣𝘪𝘯𝘢𝘳 𝘪𝘴 𝘱𝘢𝘳𝘵 𝘰𝘧 𝘢 𝘊𝘔𝘌-𝘢𝘤𝘤𝘳𝘦𝘥𝘪𝘵𝘦𝘥 𝘤𝘰𝘶𝘳𝘴𝘦 𝘢𝘯𝘥 𝘪𝘴 𝘮𝘢𝘥𝘦 𝘱𝘰𝘴𝘴𝘪𝘣𝘭𝘦 𝘵𝘩𝘢𝘯𝘬𝘴 𝘵𝘰 𝘢𝘯 𝘶𝘯𝘳𝘦𝘴𝘵𝘳𝘪𝘤𝘵𝘦𝘥 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘨𝘳𝘢𝘯𝘵 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘥 𝘣𝘺 @sanofi @Mohty_EBMT

At @ASCCANRI #RIResearchBreakfast panel discussion on the landscape of screening, treatment, research & innovation in #lungcancer. Moderator @bjork5 a survivor, advocate, podcast host & advisor to BeLUNG Here. #jnj @HinaKhanMD, @healerrance, @menonlab_uri Cheryl Ferreira

Kicking off our 2024 #RIResearchBreakfast this morning!

What a privilege to moderate this honest, heartfelt, and meaningful discussion between four superstar women leaders in hematology-oncology! #LEAD2024 #WomenInMedicine #GenderEquity #CareerDevelopment #Leadership

Great discussion as we start the 6th LEAD Annual Meeting for women in oncology - so much learning #LEAD2024

Yet another EGFR patient-centric milestone from @JNJInnovMed Congratulations to all #NSCLC #EGFR lung cancer patients and their families + the patients and investigators who participated in the MARIPOSA Ph 3 study. @Jbauml & @MAWildgust, kudos to you and your colleagues on the steady stream of innovations from and FDA approvals for @JNJInnovMed #LCSM

I am so proud to share the US FDA approval of our multi-targeted chemo-free treatment regimen for patients with newly diagnosed #EGFR #NSCLC. The priority review by the US FDA highlights the unmet need that exist and urgent need for new treatments. #MyCompany

I’m proud to share the U.S. FDA approved our chemotherapy-free combination regimen for locally advanced or metastatic EGFR-mutated #NSCLC following priority review. This is a remarkable milestone for @JNJInnovMed and everyone affected by this disease: bit.ly/4dRelbg

Thank you @JanssenUS for this opportunity to represent the caregiver journey, discuss my great love story & the significance of biomarker testing, public education and HOPE for lung cancer @TheWRP4LC @chrisdraft @AmLungCSI #LungCancerAwarenessMonth #NationalCaregiversMonth